EpimAb Biotherapeutics, a Shanghai startup, announced that it had completed the Series A funding of 25 million dollars. The funds will be used to further develop Fabs-In-Tandem Immunoglobulin (FIT-Ig), a proprietary bispecific antibody, and to expand the pipeline of bispecific antibodies for cancer immunotherapy etc. The company plans to submit an application to start the first clinical trial on FIT-Ig candidate for cancer immunotherapy during 2018.
Nikkei Biotech news release, April 27, 2017
EpimAb Biotherapeutics Co. plans clinical trials of about 2.7 billion procured tetravalent bispecific antibodies